HepaTx Receives Impact Company of the Year

​Based in Palo Alto, California, HepaTx is a biotech company specializing in developing liver disease treatments. In 2022, DotCom Magazine awarded HepaTx its Impact Company of the Year award for its innovative approach.

DotCom Magazine publishes articles and interviews about entrepreneurs, leaders, and newsmakers. The Impact Company of the Year Award recognizes privately owned companies, CEOs, founders, and staff making a positive impact and doing so through their inventive creations. The award recognizes that when businesses, their leadership, and employees positively impact their clients, this positive impact extends to the larger community.

HepaTx’s work is in regenerative medicine. The company devises new stem cell-based treatments for patients with late-stage liver disease. The company’s licensed process involves taking fat cells (adipose stromal cells), repurposing them into functional liver cells (hepatocytes), and injecting them into the liver to repair its function.

Andy Jacob, CEO of DotCom Magazine, stated that the award recognizes entrepreneurs and leaders' dedication to their companies. Furthermore, Impact Company of the Year Award winners have the courage and passion to contribute to society in many ways. For more information on the HepaTx win, please visit the company site at Hepatx.com.

SP Investment Fund

Shop